An early-stage privately held gene therapy company needs licensing and partnering expertise for their groundbreaking platform technologies. A TCG partner, with extensive biopharmaceutical licensing and strategic transactions experience, serves in an interim leadership role, including development and implementation of licensing and strategic partnering strategies, resulting in over a dozen licenses and collaborative partnerships over five years. The relationship built from an early license agreement to a global biotechnology company led to the eventual sale of a spinout hemophilia gene therapy company to the global biotech. TCG continues to provide interim licensing and strategic transaction leadership to the gene therapy company.